Results 11 to 20 of about 238,930 (305)

Proceedings of the 15th European immunogenicity platform open symposium on immunogenicity of biopharmaceuticals

open access: yesmAbs
The European Immunogenicity Platform (EIP) celebrated the 15th edition of its Open Symposium on Immunogenicity of Biopharmaceuticals and its associated one-day workshop on 22–24 February 2024 in Lisbon.
Sophie Tourdot   +39 more
doaj   +4 more sources

A randomised trial evaluating the safety and immunogenicity of the novel single oral dose typhoid vaccine M01ZH09 in healthy Vietnamese children. [PDF]

open access: yes, 2010
BACKGROUND: The emergence of drug resistant typhoid fever is a major public health problem, especially in Asia. An oral single dose typhoid vaccine would have major advantages.
Schultsz, C   +162 more
core   +1 more source

A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity [PDF]

open access: yes, 2012
© 2012 Elsevier Ltd. All rights reservedBackground: The development of a new, more effective vaccine against tuberculosis (TB) for use in healthy and HIV-infected adults, children and infants, remains a global health priority.
Minassian, Angela M   +32 more
core   +1 more source

Immunogenicity of autoantigens [PDF]

open access: yesBMC Genomics, 2011
Autoantibodies against self-antigens have been associated not only with autoimmune diseases, but also with cancer and are even found in healthy individuals. The mechanism causing the autoantibody response remains elusive for the majority of the immunogenic antigens. To deepen the understanding of autoantibody responses, we ask whether natural-occurring,
Keller Andreas   +7 more
openaire   +3 more sources

Understanding the Supersensitive Anti-Drug Antibody Assay: Unexpected High Anti-Drug Antibody Incidence and Its Clinical Relevance

open access: yesJournal of Immunology Research, 2016
Numbers of biotherapeutic products in development have increased over past decade. Despite providing significant benefits to patients with unmet needs, almost all protein-based biotherapeutics could induce unwanted immunogenicity, which result in a loss ...
Sam Song   +3 more
doaj   +1 more source

Trastuzumab immunogenicity development in patients’ sera and in laboratory animals

open access: yesBMC Immunology, 2021
Background Immunogenicity is a major challenge in drug development and patient care. Clinicians and regulators are familiar with immunogenicity concerns of monoclonal antibody (mAb) therapeutics, growth factors and enzyme replacements.
Lobna Abdel Aziz Kilany   +3 more
doaj   +1 more source

Safety and immunogenicity of H1/IC31®, an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ lymphocyte counts greater than 350 cells/mm3: a phase II, multi-centre, double-blind, randomized, placebo-controlled trial. [PDF]

open access: yes, 2014
BACKGROUND: Novel tuberculosis vaccines should be safe, immunogenic, and effective in various population groups, including HIV-infected individuals. In this phase II multi-centre, double-blind, placebo-controlled trial, the safety and immunogenicity of ...
Said, Khadija   +67 more
core   +1 more source

Immunogenicity of Rhinoviruses

open access: yesExperimental Biology and Medicine, 1970
SummaryUniformly successful production of rabbit rhinovirus antisera depended on production of immunogens with virus concentrations of at least 107 pfu/ml. Response in pairs of rabbits immunized with the same antigen appeared to be remarkably uniform, and maximum antibody titers were attained at 38 to 45 days after beginning a relatively simple ...
M K, Cooney, G E, Kenny
openaire   +2 more sources

Properties of MHC class I presented peptides that enhance immunogenicity. [PDF]

open access: yesPLoS Computational Biology, 2013
T-cells have to recognize peptides presented on MHC molecules to be activated and elicit their effector functions. Several studies demonstrate that some peptides are more immunogenic than others and therefore more likely to be T-cell epitopes. We set out
Jorg J A Calis   +7 more
doaj   +1 more source

Randomized, Controlled Trial of the Long Term Safety, Immunogenicity and Efficacy of RTS,S/AS02(D) Malaria Vaccine in Infants Living in a Malaria-Endemic Region. [PDF]

open access: yes, 2013
The RTS,S/AS malaria candidate vaccine is being developed with the intent to be delivered, if approved, through the Expanded Programme on Immunization (EPI) of the World Health Organization.
Machera, Francisca   +104 more
core   +1 more source

Home - About - Disclaimer - Privacy